<DOC>
	<DOCNO>NCT00375427</DOCNO>
	<brief_summary>The objective study assess clinical benefit two different dose schedule zoledronic acid patient metastatic bone lesion breast cancer already treat zoledronic acid one year .</brief_summary>
	<brief_title>Safety Efficacy Zoledronic Acid Patients With Breast Cancer With Metastatic Bone Lesions</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criterion : Female patient ≥ 18 year age . Written informed consent give . Histologically confirm Stage IV breast cancer least one bone metastasis radiologically confirm . Previous treatment zoledronic acid every 34 week , 912 infusion 15 month . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Life expectancy ≥ 1 year . Exclusion criterion : More 3 month since last infusion Zoledronic Acid ( Zometa® ) . Treatments bisphosphonate Zoledronic Acid ( Zometa® ) time prior study entry . Serum creatinine &gt; 3 mg/dL ( 265 μmol/L ) calculate ( CockcroftGault formula ) creatinine clearance ( CLCr ) &lt; 30 mL/min CrCl = ( { [ 140age ( year ) ] x weight ( kg ) } / [ 72 x serum creatinine ( mg/dL ) ] ) x 0.85 Corrected ( adjust serum albumin ) serum calcium &lt; 8 mg/dl ( 2 mmol/L ) &gt; 12 mg/dL ( 3.0 mmol/L ) . Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , recurrent prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery ( e.g . extraction , implant ) . Pregnant patient ( positive pregnancy test prior study entry ) lactating patient . Women childbearing potential use effective method birth control ( e.g . abstinence , oral contraceptive implant , IUD , vaginal diaphragm sponge , condom spermicide ) . History noncompliance medical regimen potential unreliable behavior . Known sensitivity study drug ( ) class study drug ( ) . Patients severe medical condition ( ) view investigator prohibit participation study Use investigational agent last 30 day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Skeletal related event ( SRE )</keyword>
</DOC>